von Willebrand factor binds to the surface of dendritic cells and modulates peptide presentation of factor VIII

Haematologica

Volumn 101, Issue 3, 2016, Pages 309-318

  Sorvillo, Nicoletta ^a,b   Hartholt, Robin B ^a   Bloem, Esther ^a   Sedek, Magdalena ^a   ten Brinke, Anja ^a   van der Zwaan, Carmen ^a   van Alphen, Floris P ^a   Meijer, Alexander B ^c,d   Voorberg, Jan ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c CENTRAL LABORATORY   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR; HLA DRB1 ANTIGEN; PEPTIDE; PROTEIN BINDING; RECOMBINANT PROTEIN;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; BINDING AFFINITY; CELL MATURATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DENDRITIC CELL; ENDOCYTOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE MUTATION; HEMOPHILIA A; HUMAN; HUMAN CELL; IMMUNOGENICITY; INTERNALIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MASS SPECTROMETRY; PROTEIN PURIFICATION; T CELL DEPLETION; AMINO ACID SEQUENCE; BINDING SITE; CELL DIFFERENTIATION; CHEMISTRY; CYTOLOGY; IMMUNOLOGY; METABOLISM; MONOCYTE; PRIMARY CELL CULTURE;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; BINDING SITES; CELL DIFFERENTIATION; DENDRITIC CELLS; ENDOCYTOSIS; FACTOR VIII; HLA-DRB1 CHAINS; HUMANS; MONOCYTES; PEPTIDES; PRIMARY CELL CULTURE; PROTEIN BINDING; RECOMBINANT PROTEINS; VON WILLEBRAND FACTOR;

EID: 84959288326     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.137067     Document Type: Article

References (40)

1. Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis. 2012;7(1):24.
2. Lillicrap D, Fijnvandraat K, Santagostino E. Inhibitors - genetic and environmental factors. Haemophilia. 2014;20(4):87-93.
3. Astermark J, Altisent C, Batorova A, et al. Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. Haemophilia. 2010;16(5):747-766.
4. Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol. 2013;4(1):59-72.
5. Gouw SC, van den Berg HM, Oldenburg J, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and metaanalysis. Blood. 2012;119(12):2922-2934.
6. Eckhardt CL, Astermark J, Nagelkerke SQ, et al. The Fc gamma receptor IIa R131H polymorphism is associated with inhibitor development in severe hemophilia A. J Thromb Haemost. 2014;12(8):1294-1301.
7. Pavlova A, Delev D, Lacroix-Desmazes S, et al. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J Thromb Haemost. 2009; 7(12):2006-2015.
8. Gouw SC, van der Bom JG, van den Berg MH. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007; 109(11):4648-4654.
9. van Haren SD, Herczenik E, ten Brinke A, Mertens K, Voorberg J, Meijer AB. HLADR- presented peptide repertoires derived from human monocyte-derived dendritic cells pulsed with blood coagulation factor VIII. Mol Cell Proteomics. 2011; 10(6):M110.002246.
10. van Haren SD, Wroblewska A, Herczenik E, et al. Limited promiscuity of HLA-DRB1 presented peptides derived of blood coagulation factor VIII. PLoS One. 2013;8(11):e80239.
11. Zhou Y-F, Eng ET, Zhu J, et al. Sequence and structure relationships within von Willebrand factor. Blood. 2012;120(2):449- 458.
12. Yee A, Gildersleeve RD, Gu S, et al. A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice. Blood. 2014;124(3):445-52.
13. Dasgupta S, Repessé Y, Bayry J, et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood. 2007;109(2):610- 612.
14. van den Biggelaar M, Bierings R, Storm G, Voorberg J, Mertens K. Requirements for cellular co-trafficking of factor VIII and von Willebrand factor to Weibel-Palade bodies. J Thromb Haemost. 2007;5(11):2235-2242.
15. Castro-Núñez L, Dienava-Verdoold I, Herczenik E, Mertens K, Meijer AB. Shear stress is required for the endocytic uptake of the factor VIII-von Willebrand factor complex by macrophages. J Thromb Haemost. 2012;10(9):1929-1937.
16. Leyte A, Mertens K, Distel B, et al. Inhibition of human coagulation factor VIII by monoclonal antibodies. Mapping of functional epitopes with the use of recombinant factor VIII fragments. Biochem J. 1989;263(1):187-194.
17. van Den Brink EN, Turenhout EA, Davies J, et al. Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes. Blood. 2000; 95(2):558-563.
18. Herczenik E, van Haren SD, Wroblewska A, et al. Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain. J Allergy Clin Immunol. 2012; 129(2):501-509.
19. van Helden PMW, van den Berg HM, Gouw SC, et al. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A. Br J Haematol. 2008;142(4):644-652.
20. Stel H V, Sakariassen KS, Scholte BJ, et al. Characterization of 25 monoclonal antibodies to factor VIII-von Willebrand factor: relationship between ristocetin-induced platelet aggregation and platelet adherence to subendothelium. Blood. 1984; 63(6):1408-1415.
21. Wroblewska A, van Haren SD, Herczenik E, et al. Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice. Blood. 2012;119(22):5294-5300.
22. Sorvillo N, van Haren SD, Kaijen PH, et al. Preferential HLA-DRB1*11-dependent presentation of CUB2-derived peptides by ADAMTS13-pulsed dendritic cells. Blood. 2013;121(17):3502-3510.
23. Nielsen M, Lundegaard C, Lund O. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics. 2007;8(1):238.
24. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood. 1998; 92(11):3983-3996.
25. Wroblewska A, Reipert BM, Pratt KP, et al. Dangerous liaisons: how the immune system deals with factor VIII. J Thromb Haemost. 2013;11(1):47-55.
26. Doherty GJ, McMahon HT. Mechanisms of Endocytosis. Annu Rev Biochem. 2009; 78(1):857-902.
27. Liu Z, Roche PA. Macropinocytosis in phagocytes: regulation of MHC class-IIrestricted antigen presentation in dendritic cells. Front Physiol. 2015;6:1.
28. Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol. 2005;23(1):975-1028.
29. Lenting PJ, Christophe OD, Denis CV. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood. 2015;125(13):2019-2028.
30. Rydz N, Swystun LL, Notley C, et al. The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels. Blood. 2013;121(26):5228-5237.
31. Pegon JN, Kurdi M, Casari C, et al. Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5. Haematologica. 2012;97(12):1855-1863.
32. Ogiwara K, Swystun L, Brown C, et al. Abstract OR332: Scavenger receptor class A member 5 (SCARA5) binds and internalizes VWF in vitro: a novel candidate VWF clearance receptor. J Thromb Haemost. 2015; 13(1):222.
33. Lenting PJ, VAN Schooten CJM, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost. 2007;5(7):1353-1360.
34. Van Schooten CJ, Shahbazi S, Groot E, et al. Macrophages contribute to the cellular uptake of Von Willebrand factor and factor VIII in vivo. Blood. 2008;112(5):1704-1712.
35. Rastegarlari G, Pegon JN, Casari C, et al. Macrophage LRP1 contributes to the clearance of von Willebrand factor. Blood. 2012; 119(9):2126-2134.
36. Mannucci PM, Federici AB. Antibodies to von Willebrand factor in von Willebrand disease. Advances in experimental medicine and biology. 1995;386(1):87-92.
37. James PD, Lillicrap D. The molecular characterization of von Willebrand disease: good in parts. Br J Haematol. 2013; 161(2):166-76.
38. Jones TD, Phillips WJ, Smith BJ, et al. Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII. J Thromb Haemost. 2005;3(5):991-1000.
39. Steinitz KN, van Helden PM, Binder B, et al. CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice. Blood. 2012;119(17): 4073-4082.
40. Oldenburg J, Lacroix-Desmazes S, Lillicrap D. Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity. Haematologica. 2015; 100(2):149- 156.